Hollie Franklin, Author at Drugs in Context

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil

Edgardo Kaplinsky MD, Gordon Mallarkey PhD

Article Type

Review

Published

23 Apr 2018

This article examines omecamtiv mecarbil, which is a first-in-class cardiac myosin activator used in the treatment of heart failure.

Emollient treatment of atopic dermatitis: latest evidence and clinical considerations

Kam Lun Hon MBBS, MD, FAAP, FCCM, Jeng Sum Charmaine Kung BSc, Wing Gi Gigi Ng BSc, Ting Fan Leung MBChB, MD, MRCP, FRCPCH

Article Type

Review

Published

17 Apr 2018

This article reviews current classes of emollients in the market, their clinical evidence in atopic dermatitis and considerations for choice of an emollient.

Administration of intravenous morphine for acute pain in the emergency department inflicts an economic burden in Europe

Montserrat Casamayor MD, PhD, Karen DiDonato MSN, RN, Marc Hennebert MBA, MS, Luca Brazzi MD, PhD, Gregor Prosen MD, FEBEM

Article Type

Original Research

Published

11 Apr 2018

This article estimates the burden of IV administration of morphine in the five key European countries (EU5) using a micro-costing approach.

Atopic dermatitis: a review of topical nonsteroid therapy

Ariana Papier BA, Lindsay C Strowd MD

Article Type

Review

Published

04 Apr 2018

This review focuses on the safety and efficacy of topical calcineurin and PDE4 inhibitors for the treatment of atopic dermatitis.

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease

Constantine E Kosmas MD, PhD, Ian Martinez MD, Andreas Sourlas, Kyriaki V Bouza MD, Frederick N Campos MD, Verenisse Torres MD, Peter D Montan MD, Eliscer Guzman MD

Article Type

Review

Published

28 Mar 2018

This review aims to present and discuss the current clinical and scientific evidence pertaining to the significance of HDL functionality over the actual HDL-C concentration in mediating the favorable effects on the cardiovascular system.